Hepatic and renal safety profile of tenofovir in HIV-infected patients with hepatitis C, including patients on interferon plus ribavirin.

@article{SnchezConde2005HepaticAR,
  title={Hepatic and renal safety profile of tenofovir in HIV-infected patients with hepatitis C, including patients on interferon plus ribavirin.},
  author={Matilde S{\'a}nchez-Conde and Paloma Gil and Mar S{\'a}nchez-Somolinos and J. Gonz{\'a}lez-lahoz and Vicente Soriano},
  journal={HIV clinical trials},
  year={2005},
  volume={6 5},
  pages={278-80}
}
The liver safety of tenofovir (TDF) was investigated in 142 HIV+ patients exposed to the drug for longer than 12 months. No evidence of liver enzyme elevations were seen, even in 66 patients with chronic hepatitis C virus (HCV) co-infection. Given that TDF is an adenosine analogue, like didanosine, exposure to ribavirin might increase intracellular phosphorylated TDF metabolites, which could result in a higher risk of nephrotoxicity. Signs of tubular dysfunction in blood or urine were not… CONTINUE READING